ERBB2 and congenital rubella syndrome: Notably, upon activation through HER2 antigen recognition and subsequent CD147 signaling, CAR-M cells have demonstrated the ability to substantially reduce cytokine levels associated with CRS, including TNF-α and IL-6, thereby lowering the risk of severe or fatal CRS [122].